C
Chaim Shustik
Researcher at McGill University Health Centre
Publications - 69
Citations - 7854
Chaim Shustik is an academic researcher from McGill University Health Centre. The author has contributed to research in topics: Multiple myeloma & Population. The author has an hindex of 27, co-authored 67 publications receiving 7039 citations. Previous affiliations of Chaim Shustik include McGill University & University of British Columbia.
Papers
More filters
Journal ArticleDOI
International staging system for multiple myeloma.
Philip R. Greipp,Jesús F. San Miguel,Brian G.M. Durie,John Crowley,Bart Barlogie,Joan Bladé,Mario Boccadoro,J. Anthony Child,Hervé Avet-Loiseau,Robert A. Kyle,Juan J. Lahuerta,Heinz Ludwig,Gareth J. Morgan,R. L. Powles,Kazuyuki Shimizu,Chaim Shustik,Pieter Sonneveld,Patrizia Tosi,Ingemar Turesson,Jan Westin +19 more
TL;DR: The new International Staging System (ISS) is simple, based on easy to use variables (Sbeta2M and serum albumin), and recommended for early adoption and widespread use.
Journal ArticleDOI
Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group
Robert A. Kyle,J. Anthony Child,Kenneth C. Anderson,Bart Barlogie,Régis Bataille,William I. Bensinger,Joan Bladé,Mario Boccadoro,William S. Dalton,Meletios A. Dimopoulos,Benjamin Djulbegovic,Mark T. Drayson,Brian G.M. Durie,Thiery Facon,Rafael Fonseca,Gösta Gahrton,Philip R. Greipp,Jean Luc Harousseau,David P. Harrington,Mohamad A. Hussein,Douglas E. Joshua,Heinz Ludwig,Gareth J. Morgan,Martin M. Oken,R. L. Powles,Paul G. Richardson,David Roodman,Jesús F. San Miguel,Kazuyuki Shimizu,Chaim Shustik,Bhawna Sirohi,Pieter Sonneveld,Guido J Tricot,Ingemar Turesson,Brian G Van Ness,David H. Vesole,Donna M. Weber,Jan Westin,Keith Wheatley +38 more
TL;DR: The International Myeloma Working Group has reviewed the criteria for diagnosis and classification with the aim of producing simple, easily used definitions based on routinely available investigations to facilitate comparison of therapeutic trial data.
Journal ArticleDOI
Pomalidomide alone or in combination with low-dose dexamethasone in relapsed and refractory multiple myeloma: a randomized phase 2 study.
Paul G. Richardson,David S. Siegel,Ravi Vij,Craig C. Hofmeister,Rachid Baz,Sundar Jagannath,Christine Chen,Sagar Lonial,Andrzej Jakubowiak,Nizar J. Bahlis,Kevin W. Song,Andrew R. Belch,Noopur Raje,Chaim Shustik,Suzanne Lentzsch,Martha Q. Lacy,Joseph R. Mikhael,Jeffrey Matous,David H. Vesole,Min Chen,Mohamed H. Zaki,Christian Jacques,Zhinuan Yu,Kenneth C. Anderson +23 more
TL;DR: POM+LoDEX was effective and generally well tolerated and provides an important new treatment option for RRMM patients who have received multiple prior therapies.
Journal ArticleDOI
ABVD Alone versus Radiation-Based Therapy in Limited-Stage Hodgkin's Lymphoma
Ralph M. Meyer,Mary Gospodarowicz,Joseph M. Connors,Robert Pearcey,Woodrow Wells,Jane N. Winter,Sandra J. Horning,A. Rashid Dar,Chaim Shustik,Douglas A. Stewart,Michael Crump,Marina S. Djurfeldt,Bingshu E. Chen,Lois E. Shepherd +13 more
TL;DR: Among patients with Hodgkin's lymphoma, ABVD therapy alone, as compared with treatment that included subtotal nodal radiation therapy, was associated with a higher rate of overall survival owing to a lower rate of death from other causes.
Journal ArticleDOI
Phase 3 Trial of Ibrutinib plus Rituximab in Waldenström’s Macroglobulinemia
Meletios A. Dimopoulos,Alessandra Tedeschi,Judith Trotman,Ramón García-Sanz,David MacDonald,Véronique Leblond,Beatrice Mahe,Charles Herbaux,Constantine S. Tam,Lorella Orsucci,M. Lia Palomba,Jeffrey Matous,Chaim Shustik,Efstathios Kastritis,Steven P. Treon,Jianling Li,Zeena Salman,Thorsten Graef,Christian Buske +18 more
TL;DR: Among patients with Waldenström's macroglobulinemia, theUse of ibrutinib–rituximab resulted in significantly higher rates of progression‐free survival than the use of placebo–ritUXimab, both among those who had received no previous treatment and among those with disease recurrence.